Overview
Crystagen is a short peptide bioregulator marketed as supporting lymphoid tissue and immune system function. It belongs to the same family of short peptide bioregulators developed under the research programme associated with Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in Russia, alongside related compounds such as Thymalin and Vesugen, which are also claimed to target immune and thymic tissue.
Important evidence context: the Khavinson bioregulator peptide research programme has produced a large volume of publications, but the overwhelming majority originate from Russian-language journals and the originating institute itself, with very limited independent replication in Western (EU/US/UK) peer-reviewed literature or by research groups outside this programme. Crystagen specifically has minimal presence in PubMed-indexed, English-language, independently authored research. This guide treats that evidence gap honestly rather than presenting bioregulator marketing claims as validated science. This guide is for educational and research purposes only. Not medical advice.
Clinical & Research Status
| Evidence Type |
Status |
| Human RCT |
Limited — claimed within the originating Russian research programme; not independently replicated in Western peer-reviewed literature |
| Observational |
Limited — within the same originating research programme only |
| Animal Studies |
Limited — reported within the originating programme's publications |
| In Vitro |
Limited — reported within the originating programme's publications |
| Regulatory Approval |
✗ (not approved by EMA, HPRA, FDA or comparable Western regulators) |
Mechanism of Action
Short peptide bioregulators in the Khavinson programme are typically composed of very short amino acid sequences (often 2-4 amino acids) that are proposed to act as gene-regulatory signalling molecules capable of penetrating cell membranes and nuclei to influence tissue-specific gene expression. The proposed theoretical framework — sometimes described as "peptide bioregulation" — suggests that these short peptides mimic naturally occurring regulatory peptides found in specific tissues, and that supplying a tissue-specific peptide bioregulator could support the function of the corresponding organ or tissue type as it ages.
For Crystagen specifically, the claimed mechanism relates to support of lymphoid tissue and broader immune system regulation, proposed to work through gene-expression modulation in lymphocytes or related immune cell populations. It is important to note that this mechanistic framework itself is not part of mainstream Western molecular biology or immunology and has not been validated through the kind of large-scale, independently replicated mechanistic studies applied to better-characterised peptides in this library, such as Ipamorelin or BPC-157. Readers should treat the proposed mechanism as a claim originating from a specific research programme rather than an established biological pathway.
Research Areas & Reported Effects
Immune and Lymphoid Tissue Support (Claimed)
Publications from the originating research programme report investigations into Crystagen's effects on lymphoid organ function and immune parameters, primarily in the context of ageing-related immune decline (immunosenescence) in animal models and, per programme literature, in some human observational contexts. Independent verification of these specific findings outside the originating group is not established in the accessible Western literature.
Positioning Within the Broader Bioregulator Peptide Family
Crystagen is most commonly discussed alongside other tissue-specific short peptide bioregulators from the same programme (e.g., Thymalin for thymus, Vesugen for vascular tissue, Testagen for testicular tissue). Much of the available context on Crystagen comes from this comparative framework rather than compound-specific independent research.
Research Data Summary
| Study / Model |
Reported Effect |
| Originating institute publications (Khavinson V et al., various) |
Reported support of lymphoid tissue function and immune parameters in ageing models; not independently replicated in Western peer-reviewed literature at the compound-specific level. |
| Independent Western peer-reviewed replication |
Not identified in accessible English-language, PubMed-indexed literature at time of writing. |
Stack Combinations Studied
Within Khavinson programme literature, bioregulator peptides are sometimes described as usable alongside other tissue-specific bioregulators from the same family (e.g., paired with Thymalin for combined thymic/lymphoid support). This pairing rationale originates entirely from within the programme's own publications and has not been independently validated. No Western peer-reviewed stacking research exists.
⚠️ No independently verified stack research exists for this compound. This section is intentionally left without fabricated combinations.
Research Protocol Reference
experimental research protocols only — not dosing recommendations. Protocol figures below are drawn from programme-published sources and have not been independently validated by Western regulatory or academic bodies.
| Protocol |
Dose (as reported in originating programme literature) |
Duration (as reported) |
Frequency (as reported) |
Research Context |
| Bioregulator Programme Protocol (as published by originating institute) |
Not independently verified; oral capsule formulations reported in programme literature |
Reported as short courses (e.g., 10-30 days) in programme literature |
Reported as periodic/cyclical courses in programme literature |
Immune/lymphoid tissue support research within the originating programme. |
Observed Side Effects in Research
- No independently published, peer-reviewed Western safety or tolerability data exists for Crystagen specifically
- Originating programme literature reports no significant adverse events, but this has not been independently verified
- No human pharmacokinetic data exists in accessible Western literature
Because independent verification of Crystagen's safety profile is not available in Western peer-reviewed literature, no independently validated side-effect profile can be provided. This is a significant limitation of the evidence base.
Compound Data
- CAS Number
- Not consistently assigned or independently verified in Western chemical registries
- Molecular Formula
- Not consistently published in independently verifiable Western sources
- Molecular Weight
- Not independently verified; short peptide bioregulators in this family are typically very low molecular weight (di- to tetrapeptide range)
- Half-Life
- Not established in independently published pharmacokinetic literature
- Synonyms
- Crystagen (Khavinson bioregulator series); no other widely used synonyms identified
- Research Classification
- Short peptide bioregulator, claimed lymphoid/immune tissue support; Russian bioregulator research programme, minimal independent Western verification
Scientific References
Note on evidence base: This is a limited and largely non-Western evidence base. Nearly all identifiable publications relating to Crystagen originate from the Khavinson research programme itself or affiliated Russian-language journals. There is no substantive independent replication in PubMed-indexed, English-language literature by unaffiliated research groups. This should be read as a claims-based, programme-internal evidence base rather than a broadly validated one, and is presented here for completeness and transparency rather than as an endorsement of efficacy.
- [Khavinson VK et al.] — Peptide regulation of ageing: results and prospects of research on short peptide bioregulators. — Bulletin of Experimental Biology and Medicine — [Originating programme, review]
- [Khavinson VK, Malinin VV] — Gerontological aspects of genome peptide regulation. — Karger (monograph) — [Originating programme, review]
*This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.*